SAN DIEGO--(BUSINESS WIRE)--Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte™ technology platform at the American Association for Cancer Research (AACR) annual meeting March 29 – April 3, at the Georgia World Congress Center in Atlanta.
Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.
“Cytonus Therapeutics will be presenting preclinical data from our growing oncology pipeline that supports the versatility of our Cargocytes as a groundbreaking allogeneic, off-the-shelf, immune-therapy platform,” said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus. “Our preclinical results in our Triple Negative Breast Cancer model experiments are impressive and exciting. We are able to demonstrate that 40 percent of our animals being treated with our Cargocyte associated IL-12 are showing no sign of disease more than 260 days post treatment where as our control animals are dying typically 25 to 30 days into the experiments. These experiments are still ongoing and our mice are doing well. We have replicated these studies multiple times and have found the pattern to exist.”
Details of the presentation:
Abstract Title: Cargocytes: A novel cell therapy platform to drive anti-tumor immunity
Session Category: Immunology
Session Title: Late-Breaking Research: Immunology 1
Session Date and Time: Monday, April 1, 2019 8:00 AM - 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 41
Poster Board Number: 12
Permanent Abstract Number: LB-067
Cytonus will also be presenting at:
Association Society of Gene and Cell Therapy (ASGCT), April 29-May 2, 2019 in Washington, D.C.
Bio International Convention, June 3-6, 2019 in Philadelphia
Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes™. The San Diego-based company’s proprietary Cargocyte™ platforms are cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf cellular therapy for the potential treatment of several diseases across multiple therapeutic areas. Cytonus’ initial focus is to advance Cargocyte™ candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases. For more information, visit www.cytonus.com or follow us on LinkedIn.
Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.